Press Releases

– Dry Eye Disease Phase 2 Study Remains on Track – Data Anticipated in 4Q20 – $89 Million in Cash at March 31, 2020 CRANBURY, N.J., April 30, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic […]

– Study Results Expected Q4 2020 Feb 19, 2020, 07:30 ET CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it has enrolled the first patient

— Dry Eye Disease Phase 2 Study to Commence Q1 2020 — Data Q4 2020 — Approximately $92 Million in Cash and Cash Equivalents at December 31, 2019 — AMAG Announced Plans to Divest Vyleesi® for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) — Teleconference and Webcast to be held on February 11, 2020

Feb 06, 2020, 07:30 ET CRANBURY, N.J., Feb. 6, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2020 operating results on Tuesday, February 11, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

– Vyleesi® for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) – AMAG to Divest Asset – Dry Eye Disease Phase 2 Study to Commence Q1 2020 – Data Q4 2020 – Approximately $92 Million in Cash and Cash Equivalents at December 31, 2019 Jan 21, 2020, 07:30 ET CRANBURY, N.J., Jan. 21, 2020 /PRNewswire/

Vyleesi™ launched nationally in September Teleconference and Webcast to be held on November 13, 2019 CRANBURY, N.J., Nov. 13, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted,

Nov 07, 2019, 07:30 ET CRANBURY, N.J., Nov. 7, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

CRANBURY, N.J., Oct. 17, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin’s Vice President of Pre-Clinical Development, provided a presentation on Palatin’s oral colon delivery formulation, PL8177 in development for the treatment of ulcerative colitis, at the 7th CPC Symposium on Peptide Therapeutics in Hangzhou, China. Dr. Dodd

Oct 16, 2019, 07:00 ET CRANBURY, N.J., Oct. 16, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced today that data from two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and the Exit Survey/Interview data on Vyleesi™ (bremelanotide injection) for hypoactive sexual desire disorder (HSDD) will be presented at the 13th European Society of

Teleconference and Webcast to be held on September 12, 2019 Sep 12, 2019, 07:30 ET CRANBURY, N.J., Sept. 12, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific